Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Complete a sprint project to deliver clinical material for the investigational anti-growth hormone receptor (GHR) antibody.
March 6, 2025
By: Charlie Sternberg
ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002, Marea’s investigational anti-growth hormone receptor (GHR) antibody for the treatment of acromegaly. The partnership encompassed cell line development, process development, formulation development, and GMP manufacturing services.
The collaboration leveraged ProBioGen’s CHO.RiGHT cell line development platform, including its proprietary DirectedLuck transposase technology, to generate superior, high-yielding clone pools for early material production for IND-enabling toxicology studies. The stable platform also enabled the development of a robust, scalable manufacturing process, including integrated, seamless drug product (DP) manufacturing at Marea’s DP partner, contributing to the successful development of MAR002.
“We are pleased to have successfully completed this comprehensive project with Marea Therapeutics, delivering on our commitment to high quality and accelerated timelines,” said Dr. Alfred Merz, CEO of ProBioGen. “This collaboration exemplifies our customer-centric approach and our ability to support biotech companies with innovative and flexible solutions, enabling a sprint to IND to meet their challenging timelines. We look forward to seeing the continued progress of MAR002.”
Mark Joing, Chief Development Operations Officer of Marea, added: “MAR002 holds promise as a first-in-class treatment for acromegaly, a life-shortening disease often with serious complications. We appreciate ProBioGen’s support throughout the process and look forward to continuing our collaboration as we advance to the next stages.”
The partnership between ProBioGen and Marea Therapeutics has successfully laid the foundation for MAR002’s next development stages. With key CMC milestones achieved, Marea is well-positioned to advance the candidate further toward clinical and commercial readiness.
ProBioGen recently expanded both protein and virus manufacturing at its Berlin headquarters.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
